Results 121 to 130 of about 97,885 (294)

Microbiome in atopic dermatitis

, 2017
Uwe Wollina Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany Abstract: Atopic dermatitis (AD) is a common chronic inflammatory skin disease affecting ~10–20% of the general population ...
Wollina U
core  

Healthcare Service Utilization by 116,816 Patients with Atopic Dermatitis in Israel

Acta Dermato-Venereologica, 2019
Understanding of the epidemiology and healthcare service utilization related to atopic dermatitis is necessary to inform the use of new treatments. This cross-sectional study was based on a group of patients with atopic dermatitis and a matched control ...
Guy Shalom, Meir Babaev, Khalaf Kridin, Yochai Schonmann, Amir Horev, Jacob Dreiher, Michal Shani, Shmuel Tiosano, Shani Fisher, Doron Comaneshter, Arnon D. Cohen   +10 more
doaj   +1 more source

Topical tacrolimus as treatment of atopic dermatitis

, 2009
Masutaka Furue, Satoshi TakeuchiDepartment of Dermatology, Faculty of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease.
Masutaka Furue, Satoshi Takeuchi
core  

Guidelines for treatment of atopic eczema (atopic dermatitis) Part II

, 2012
The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national standard Appraisal of Guidelines Research and Evaluation.
European Federation of Allergy,, U. Darsow, Asthma European Network, European Federation of Allergy, Simon, D, T. Luger, U. Gieler, Szalai, S., Ständer, S, Szalai, S, Gelmetti, C, Global Allergy and Asthma European Network (GA2LEN),, Schwennesen, T., Alomar, A, Darsow, U, European Academy of Dermatology, Stingl, G, GA²LEN Study Group (), Bieber, T., Seidenari, S, Global Allergy, Wollenberg, A., J. Lipozencic, Werfel, T, Fink-Wagner, A., A. Taïeb, Bieber, T, European Task Force on Atopic Dermatitis (ETFAD),, S. Ständer, European Society of Pediatric Dermatology, A. P. Oranje, Gieler, U., European Federation of Allergy (EFA),, Schäfer, T., Seidenari, S., Global Allergy and Asthma European Network,, T. Werfel, Deleuran, M., G. Stingl, Taïeb, A., European Society of Pediatric Dermatology (ESPD),, Simon, D., D. Simon, Ring, J, Gieler, U, European Federation of Allergy (EFA) (), European Task Force on Atopic Dermatitis (ETFAD) (), Gelmetti, C., European Dermatology Forum, European Task Force on Atopic Dermatitis,, J. Ring, European Academy of Dermatology and Venereology (EADV) (), T. Bieber, European Society of Pediatric Dermatology (ESPD) (), Szepietowski, J C, Werfel, T., T. Schwennesen, Schäfer, T, S. Seidenari, C. Gelmetti, European Dermatology Forum (EDF) (), Fink-Wagner, A, Luger, T., European Academy of Dermatology and Venereology (EADV),, Deleuran, M, A. Wollenberg, Ständer, S., Oranje, A P, European Task Force on Atopic Dermatitis, Alomar, A., European Academy of Dermatology and Venereology,, Lipozencic, J., Darsow, U., Stingl, G., Szepietowski, J.C., A. Alomar, M. Deleuran, Schwennesen, T, Oranje, A.P., A. Fink Wagner, S. Szalai, Ring, J., Luger, T, Wollenberg, A, Lipozencic, J, European Dermatology Forum,, European Dermatology Forum (EDF),, Venereology, J. C. Szepietowski, European Society of Pediatric Dermatology,, T. Schäfer, Taïeb, A   +91 more
core   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, Volume 5, Issue 2, Page 529-537, June 2026.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Gut microbiota modulation: a key determinant of atopic dermatitis susceptibility in children

Frontiers in Microbiology
Atopic dermatitis is a chronic inflammatory skin condition with a higher incidence rate among children. In recent years, the role of the gut microbiota in the pathogenesis of atopic dermatitis has garnered increasing attention. This review systematically
Huimiao Tang, Huimiao Tang, Wenxin Li, Yidan Xu, Yidan Xu, Yanjun Zhou, Yanjun Zhou, Michael R. Hamblin, Xiang Wen, Xiang Wen   +9 more
doaj   +1 more source

Steroid Phobia and Management Issues of Atopic Dermatitis - The Hong Kong Perspective

, 2019
Steroid phobia and various misconceptions about atopic dermatitis are common, contributing to treatment failure in management of childhood asthma. Exploration of parental concerns and provision of education and support are keys to successful management.
Leung, TNH
core  

Emollient treatment of atopic dermatitis: latest evidence and clinical considerations

, 2018
Aim: To review current classes of emollients in the market, their clinical efficacy in atopic dermatitis (AD) and considerations for choice of an emollient.
Wing Gi Gigi Ng, Jeng Sum Charmaine Kung, Kam Lun Hon, Ting Fan Leung   +3 more
core   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study

JEADV Clinical Practice, EarlyView.
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio, Gabriele Roccuzzo, Iria Neri, Alessandro Pileri, Alessandro Svizzero, Maria Beatrice De Felici Del Giudice, Vieri Grandi, Pietro Quaglino, Valeria Brazzelli   +8 more
wiley   +1 more source